BRE-10: Biomarker Optimization of Neoadjuvant Therapy in Breast Cancer
Trial statusRecruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age18+
SponsorUniversity of Illinois at Chicago
About this trial
Adult men and women with early-stage, IHC/FISH-defined HER2-positive breast cancer will have a MammaPrint®/BluePrint® assay performed on the diagnostic biopsy specimen, ordered by the treating Oncologist as standard care
Eligibility criteria
Qualifiers
Age ≥ 18 years of age at time of consent
ECOG performance status 0, 1, or 2
Histologically confirmed invasive breast cancer documented by core needle or surgical biopsy with 90 days prior to study registration.
HER2-positive by IHC or FISH according to ASCO/CAP 2018 guidelines
Disqualifiers
Any prior therapy for this breast cancer
Active infection requiring systemic therapy at the time of study registration
Pregnant or nursing
Any prior or concurrent malignancy whose natural history or treatment has the potential to interfere with the safety or efficacy assessment of this investigational regimen, as determined by the treating medical oncologist.
Trial design
Treatments tested in this trial
- Paclitaxel
- Nab-paclitaxel
- Docetaxel
- Trastuzumab
- Pertuzumab
Treatment groups
28 Participants
are divided into 1 treatment groupSponsors and collaborators
Source ClinicalTrials.gov